Paradigm shift in the treatment of bladder cancer? The Swedish perspective
DOI:
https://doi.org/10.2340/sju.v60.44464Keywords:
Bladder Cancer, Mortality and Survival, national registriesAbstract
N/A
Downloads
References
Malmström PU. Bladder tumours: time for a paradigm shift? BJU Int. 2011 May;107(10):1543–1545. https://doi.org/10.1111/j.1464-410X.2011.10235.x DOI: https://doi.org/10.1111/j.1464-410X.2011.10235.x
Gagliardi J. Bladder cancer mortality rate in Europe 2022, by country and gender [Internet]. Statista; 2022 [cited 2025 Mar 30]. Available from: https://www.statista.com/statistics/1452400/bladder-cancer-mortality-rate-in-europe-by-country-and-gender/
Malmström PU, Gårdmark T, Sherif A, et al. Incidence, survival and mortality trends of bladder cancer in Sweden 1997–2016. Scand J Urol. 2019 Aug;53(4):193–199. https://doi.org/10.1080/21681805.2019.1632380 DOI: https://doi.org/10.1080/21681805.2019.1632380
Wang EYH, Pihlström N, Malmström PU, et al. Improved long-term outcome of patients with non-muscle invasive, low and intermediate risk bladder cancer between 1997 and 2014; a Swedish population-based study. Scand J Urol. 2022 Jun;56(3):221–226. https://doi.org/10.1080/21681805.2022.2062046 DOI: https://doi.org/10.1080/21681805.2022.2062046
Sylvester RJ, Oosterlinck W, Holmang S, et al. Systematic review and individual patient data meta-analysis of randomized trials comparing a single immediate instillation of chemotherapy after transurethral resection with transurethral resection alone in patients with stage pTa-pT1 urothelial carcinoma of the bladder: which patients benefit from the instillation? Eur Urol. 2016 Feb;69(2):231–244. https://doi.org/10.1016/j.eururo.2015.05.050 DOI: https://doi.org/10.1016/j.eururo.2015.05.050
Regionala Cancercentrum i Samverkan. National Swedish guidelines on bladder cancer [Internet]. Published YEAR [cited 2025 Jan 15]. Available from: https://cancercentrum.se/samverkan/cancerdiagnoser/urinblasa-urinvagar/
Wang EY, Larsson U, Gårdmark T, et al. Radical cystectomy compared to intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer – is there a long-term survival difference? A Swedish nationwide analysis. Scand J Urol. 2021 Feb;55(1):46–52. https://doi.org/10.1080/21681805.2020.1851763 DOI: https://doi.org/10.1080/21681805.2020.1851763
Sylvester RJ, van der Heijden AG, Witjes JA, et al. European Association of Urology (EAU) prognostic factor risk groups for non-muscle-invasive bladder cancer (NMIBC) incorporating the WHO 2004/2016 and WHO 1973 classification systems for grade: an update from the EAU NMIBC Guidelines Panel. Eur Urol. 2021;79(4):480–487. https://doi.org/10.1016/j.eururo.2020.12.033 DOI: https://doi.org/10.1016/j.eururo.2020.12.033
Yin M, Joshi M, Meeks JJ, et al. Neoadjuvant chemotherapy for muscle-invasive bladder cancer: a systematic review and two-step meta-analysis. Oncologist. 2016;21(6):708–715. https://doi.org/10.1634/theoncologist.2015-0440 DOI: https://doi.org/10.1634/theoncologist.2015-0440
McFerrin C, Davaro F, May A, et al. Trends in utilization of neoadjuvant and adjuvant chemotherapy for muscle-invasive bladder cancer. Investig Clin Urol. 2020 Nov;61(6):565–572. https://doi.org/10.4111/icu.20200132 DOI: https://doi.org/10.4111/icu.20200132
Gronostaj K, Czech AK, Fronczek J, et al. Changes in neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer treatment: a tertiary center retrospective study. Cent European J Urol. 2020;73(1):13–18.
Liedberg F, Hagberg O, Aljabery F, et al. Cystectomy for bladder cancer in Sweden – short-term outcomes after centralization. Scand J Urol. 2023;84(1):84–89. https://doi.org/10.2340/sju.v59.40120 DOI: https://doi.org/10.2340/sju.v59.40120
Stattin P. How to improve cancer care by use of guidelines and quality registers. Scand J Urol. 2024 Dec 12;59:190–192. https://doi.org/10.2340/sju.v59.42272 DOI: https://doi.org/10.2340/sju.v59.42272
Malmström PU, Gårdmark T. Abandoning testing for asymptomatic microscopic haematuria in Sweden – a long-term follow-up. Scand J Urol. 2023 Nov 21;58:109–114. https://doi.org/10.2340/sju.v58.11142 DOI: https://doi.org/10.2340/sju.v58.11142
Tichanek F, Försti A, Hemminki A, et al. Survival in kidney and bladder cancers in four Nordic countries through a half century. Cancers. 2023 May 16;15(10):2782. https://doi.org/10.3390/cancers15102782 DOI: https://doi.org/10.3390/cancers15102782
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Per-Uno Malmström, Eugen Y.H. Wang
This work is licensed under a Creative Commons Attribution 4.0 International License.
As from Volume 59 (2024) all published articles, unless otherwise specified, are published under CC-BY license, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, with the condition of proper attribution to the original work.
